Billy Best: The Boy Who Ran Away From Chemotherapy

awthraw queried:

So your criticism is that the site complies with FDA regulations by including that statement??

LOL ...

How dare they, the cads.

Healthfraud Terry The Terror Polevoy also seemed upset that in this
press release, they disclosed their funding. It appears he prefers the
way we have learned most research for pharmaceuticals is handled ...
the drug companies pay researchers who FAIL to disclose their ties.

Don't recall if I mentioned it ... but Billy's Mom just reported back
that he is doing great ... 11 years after running away from chemo.

Here's the press release:

--------------------------------------------------------------------------------

http://www.newswise.com/articles/view/522530/?sc=sphn

Source: American Association of Naturopathic Physicians (AANP)
Released: Wed 09-Aug-2006, 09:45 ET
Herbal Remedy Essiac® and Cancer Libraries
Medical News
Keywords ESSIAC; ESSIAC AND CANCER

Contact Information
Available for logged-in reporters only

Description

Two new studies examine the purported benefits of Essiac®, an herbal
compound often used by those with cancer.

Newswise — Essiac® is an herbal formula that has been used by North
American cancer patients. Its recorded history dates back to the 1920s
when Canadian nurse Rene Caisse blended a tea of burdock root, sheep
sorrel, slippery elm bark, and turkey rhubarb root, and offered it to
her cancer patients. It is believed she received the formulation from
an
Ojibwa Indian woman. The name Essiac is Caisse spelled backwards.

Despite its relatively widespread use, there is little published
research about this herbal remedy in the scientific literature. As a
result, two teams of Canadian researchers launched research efforts.

The first group of researchers utilized a series of assays to
determine
the validity of some of Essiac®’s purported activities in vitro; the
second group used an animal model to investigate the effects of the
mixture on the stomach, liver and immune system. Both studies were
funded by an educational grant from the manufacturer of Essiac®. The
company had no role in the collection or analysis of the data.

Both research teams are presenting their findings at the 21st Annual
Meeting of the American Association of Naturopathic Physicians
(http://www.Naturopathic.org), being held August 9-12, 2006 at the
Oregon Convention Center, Portland, OR.

Study 1: In Vitro Analysis of Herbal Compound Essiac®
The first study entitled, An In Vitro Analysis of the Herbal Compound
Essiac®, was conducted by Deborah A. Kennedy, MBA, ND (Cand.),
Division
of Clinical Epidemiology, The Canadian College of Naturopathic
Medicine,
Toronto, CN; Stephen P. Myers, PhD, BMed, ND, Phillip A. Cheras,
Ph.D.,
BAppSc., David Lin, Ph.D., Rachel Li, PhD, Trudi Cattley, BAppSc., and
Petta-Anne Paul Brent, BSc., all of the Australian Centre for
Complementary Medicine, Southern Cross University, Lismore, NSW, AU;
Dugald M.R. Seely, ND, MSc. (Cand.), Division of Clinical
Epidemiology,
The Canadian College of Naturopathic Medicine, Toronto, CN and the
Institute of Medical Science, University of Toronto, CN; and Blair
J.N.
Leonard, MD, Faculty of Medicine, University of Toronto, Toronto, CN.

Methodology
The purpose of the study was to utilize a series of assays to
determine
several of Essiac®’s purported activities in vitro. The activity of
Essiac® was measured using established in vitro assays to quantify:
(1)
antioxidant activity; (2) platelet aggregation inhibition; (3)
anti-microbial activity; (4) arachidonic acid pathway inhibition; (5)
cell-based immunomodulation; (6) neoplastic cell specific
cytotoxicity;
(7) fibrinolytic activity; and (8) inhibition of enzymes of the CYP450
pathway.

Results
Highlights of the findings showed:

§ there was significant antioxidant activity in the ABTS assay, with 1
ml of Essiac® having the anti-oxidant activity of 3mm Troxol, a
vitamin
E analogue;
§ Essiac® at 20-fold dilution showed significant immunomodulatory
effects;
§ Essiac® showed significant cell specific cytotoxicity towards
ovarian
epithelial carcinoma cells;
§ after hydrolysis with beta glucosidase, Essiac® showed increased
cytotoxicity towards prostate adenocarcinoma cells;
§ a 20-fold dilution of Essiac® showed significant inhibition of
several
cytochrome P450 enzymes;
§ Essiac® demonstrated dose-dependant inhibition of clot fibrinolysis;
and
§ Essiac® showed no specific activity in the platelet aggregation or
anti-microbial assays.

Conclusions
This analysis of Essiac® indicates significant antioxidant and
immunomodulatory properties, as well as neoplastic cell specific
cytotoxicity consistent with the historical properties ascribed to
this
compound. Importantly, significant cytochrome P450 and fibrinolysis
inhibition was also observed. These data represent the first
comprehensive investigation of the in vitro effects of Essiac®.

Study 2: An In Vivo Analysis of the Herbal Compound Essiac®
The second study entitled, An In Vivo Analysis of the Herbal Compound
Essiac®, was conducted by Blair J.N. Leonard MD, Faculty of Medicine,
University of Toronto, Toronto, ON; Deborah A. Kennedy, MBA, ND
(Cand.),
Division of Clinical Epidemiology, The Canadian College of
Naturopathic
Medicine, Toronto, CN; Fong-Chi Cheng, MDS Pharma Services-Taiwan
Ltd.,
Taipei, TW; Keng-Kuang Chang, MDS Pharma Services-Taiwan Ltd., Taipei,
TW; and Dugald M.R. Seely, ND, MSc. (Cand.), Division of Clinical
Epidemiology, The Canadian College of Naturopathic Medicine, Toronto,
CN
and the Division of Hematology/Oncology, Hospital for Sick Children,
Toronto, CN.

Methodology

The study aimed to assess some of Essiac®’s purported effects on the
liver, stomach and immune system. To do so, the researchers
administered
Essiac® liquid extract to Wistar rats under established rodent
experimental models. The rats received Essiac® 30-minutes prior to a
physical challenge to the liver, stomach or immune system. The rats
were
dosed again with the compound at 4, 8 and 24 hours. Also at 24 hours
they were sacrificed and specific levels were measured, including body
weight.

Results and Conclusions

Essiac® showed significant effects in gastric protection and
non-significant changes with other properties. Thus, the researchers
concluded that Essiac® administered in established in vivo experiments
did not significantly demonstrate the purported physiological
modifying
effects. These results are significant as they represent the first
published investigation on the in vivo effects of Essiac® consumption.

The American Association of Naturopathic Physicians (AANP) was founded
in 1985 to provide alternative methods for healing human diseases and
disorders than have been traditionally offered in the United States.
Members of the AANP must have graduated from one of North America’s
six
accredited graduate schools of naturopathic medicine.

Couldn't help notice that there is nothing about this being published in the
scientific literature. Research being presented at a meeting like this does
not count.

Jeff

wrote in message
ups.com...

CWatters wrote:
"Ilena Rose" wrote in message
...

... Essiac was one of the treatments that we decided on although it
took us awhile to wade through the counterfeits and finally settle on
the real Essiac from Resperin Corporation.

I just love the way all the Essiac web sites say something like...

http://www.resperin.ca

"This product is not intended to diagnose, treat, cure, or prevent any
disease."

So your criticism is that the site complies with FDA regulations by
including that statement??

No. It that this is the only way they can comply.

Jeff wrote:
Couldn't help notice that there is nothing about this being published in the
scientific literature. Research being presented at a meeting like this does
not count.

Jeff

What are you talking about?